ENTPD1 and neoplasm: Therapeutic strategies targeting CD39 or CD73 as well as A2BR antagonism have the potential to reverse adenosine-mediated immunosuppression, albeit only CD39 blockade will boost ATP-mediated anti-tumor immunity.